{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:32Z","timestamp":1793405312910,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-026-07081-1","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:58:08Z","timestamp":1780905488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selumetinib in the treatment of plexiform neurofibromas in neurofibromatosis type 1: a 6-year prospective case series with review of the literature"],"prefix":"10.1186","volume":"26","author":[{"given":"Francesco","family":"Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Messana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Andresani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Magnolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora Maria","family":"Murru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Spezzacatene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cattaruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Paternuosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Zanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Diplotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Michieletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"7081_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","volume":"115","author":"RE Ferner","year":"2013","unstructured":"Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939\u201355.","journal-title":"Handb Clin Neurol"},{"key":"7081_CR2","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"7081_CR3","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.esmoop.2021.100223","volume":"6","author":"I Solares","year":"2021","unstructured":"Solares I, Vi\u00f1al D, Morales-Conejo M, Rodriguez-Salas N, Feliu J. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. ESMO Open. 2021;6(4):100223.","journal-title":"ESMO Open"},{"key":"7081_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-7-75","volume":"7","author":"R Nguyen","year":"2012","unstructured":"Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7:75.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"7081_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007;68(9):643\u20137.","journal-title":"Neurology"},{"issue":"8","key":"7081_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2340\/00015555-2975","volume":"98","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y, Ehara Y, Koga M, Imafuku S, Yamamoto O. Epidemiological Analysis of Major Complications Requiring Medical Intervention in Patients with Neurofibromatosis 1. Acta Derm Venereol. 2018;98(8):753\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"7081_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3171\/jns.2005.102.2.0246","volume":"102","author":"DH Kim","year":"2005","unstructured":"Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg. 2005;102(2):246\u201355.","journal-title":"J Neurosurg"},{"issue":"26","key":"7081_CR8","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016;375(26):2550\u201360.","journal-title":"N Engl J Med"},{"issue":"15","key":"7081_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"7081_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40272-020-00399-y","volume":"22","author":"F Baldo","year":"2020","unstructured":"Baldo F, Grasso AG, Cortellazzo Wiel L, Maestro A, Trojniak MP, Murru FM, et al. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects. Paediatr Drugs. 2020;22(4):417\u201323.","journal-title":"Paediatr Drugs"},{"key":"7081_CR11","unstructured":"The Italian Data Protection Authority. Authorisation no. 9\/2014 \u2013 General Authorisation to Process Personal Data for Scientific Research Purposes. Available online at: https:\/\/www.garanteprivacy.it\/web\/guest\/home\/docweb\/-\/docweb-display\/docweb\/3786078."},{"issue":"11","key":"7081_CR12","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","volume":"24","author":"AM Gross","year":"2022","unstructured":"Gross AM, Glassberg B, Wolters PL, Dombi E, Baldwin A, Fisher MJ, et al. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol. 2022;24(11):1978\u201388.","journal-title":"Neuro Oncol"},{"issue":"10","key":"7081_CR13","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross AM, Dombi E, Wolters PL, Baldwin A, Dufek A, Herrera K, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023;25(10):1883\u201394.","journal-title":"Neuro Oncol"},{"issue":"2","key":"7081_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","volume":"147","author":"V Espirito Santo","year":"2020","unstructured":"Espirito Santo V, Passos Je, Nzwalo H, Carvalho I, Santos F, Martins C, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol. pp. 2020;147(2):459\u201363.","journal-title":"J Neurooncol"},{"key":"7081_CR15","doi-asserted-by":"crossref","unstructured":"Cacchione A, Fabozzi F, Carai A, Colafati GS, Baldo GD, Rossi S, et al. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study. Cancer Control. 2023;30:10732748221144930.","DOI":"10.1177\/10732748221144930"},{"issue":"1","key":"7081_CR16","first-page":"vdad054","volume":"5","author":"S Suenobu","year":"2023","unstructured":"Suenobu S, Terashima K, Akiyama M, Oguri T, Watanabe A, Sugeno M, et al. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study. Neurooncol Adv. 2023;5(1):vdad054.","journal-title":"Neurooncol Adv"},{"issue":"8","key":"7081_CR17","doi-asserted-by":"publisher","first-page":"e29633","DOI":"10.1002\/pbc.29633","volume":"69","author":"H Coltin","year":"2022","unstructured":"Coltin H, Perreault S, Larouche V, Black K, Wilson B, Vanan MI, et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series. Pediatr Blood Cancer. 2022;69(8):e29633.","journal-title":"Pediatr Blood Cancer"},{"key":"7081_CR18","doi-asserted-by":"crossref","unstructured":"Dai YL, Choi CS, Wiltsie L, Callahan AB. Selumetinib in the Treatment of Orbital Plexiform Neurofibroma: A Case Report. Ophthalmic Plast Reconstr Surg. 2023;39(3):e75\u20138.","DOI":"10.1097\/IOP.0000000000002330"},{"key":"7081_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2019.11.010","volume":"105","author":"J Passos","year":"2020","unstructured":"Passos J, Nzwalo H, Azevedo M, Tavares M, Nunes S. Dramatic Improvement of a Massive Plexiform Neurofibroma After Administration of Selumetinib. Pediatr Neurol. 2020;105:69\u201370.","journal-title":"Pediatr Neurol"},{"issue":"7","key":"7081_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021;39(7):797\u2013806.","journal-title":"J Clin Oncol"},{"key":"7081_CR21","doi-asserted-by":"publisher","first-page":"10504","DOI":"10.1200\/JCO.2018.36.15_suppl.10504","volume":"36","author":"GB McCowage","year":"2018","unstructured":"McCowage GB, Mueller S, Pratilas CA, Hargrave DR, Moertel CL, Whitlock J, et al. Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)\u2013associated plexiform neurofibroma: A phase I\/IIa study. J Clin Oncol. 2018;36:10504.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7081_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","volume":"27","author":"MJ Fisher","year":"2021","unstructured":"Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi, et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021;27(1):165\u201373.","journal-title":"Nat Med"},{"issue":"11","key":"7081_CR23","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1002\/cam4.3910","volume":"10","author":"R Ronsley","year":"2021","unstructured":"Ronsley R, Hounjet CD, Cheng S, Rassekh SR, Duncan WJ, Dunham C, et al. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma. Cancer Med. 2021;10(11):3556\u201364.","journal-title":"Cancer Med"},{"issue":"6","key":"7081_CR24","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00381-021-05127-6","volume":"37","author":"H Toledano","year":"2021","unstructured":"Toledano H, Dotan G, Friedland R, Cohen R, Yassur I, Toledano-Alhadef H, et al. Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1. Childs Nerv Syst. 2021;37(6):1909\u201315.","journal-title":"Childs Nerv Syst"},{"issue":"5","key":"7081_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0039-1691830","volume":"50","author":"P Vaassen","year":"2019","unstructured":"Vaassen P, D\u00fcrr N, R\u00f6hrig A, Willing R, Rosenbaum T. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery. Neuropediatrics. 2019;50(5):300\u20133.","journal-title":"Neuropediatrics"},{"issue":"9","key":"7081_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","volume":"61","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61(9):1598\u2013602.","journal-title":"Pediatr Blood Cancer"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07081-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:39:01Z","timestamp":1786675141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-07081-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7081"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-07081-1","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study or, in case of individuals younger than the age of 18, from their parents.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of clinical details and\/or clinical images was obtained from the patients or their parents.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"750"}}